233 related articles for article (PubMed ID: 25629143)
1. Glycopyrronium + indacaterol. A fixed-dose combination with no advantages in COPD.
Prescrire Int; 2014 Dec; 23(155):288. PubMed ID: 25629143
[TBL] [Abstract][Full Text] [Related]
2. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T
Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448
[TBL] [Abstract][Full Text] [Related]
3. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
Prakash A; Babu KS; Morjaria JB
Int J Chron Obstruct Pulmon Dis; 2015; 10():111-23. PubMed ID: 25609944
[TBL] [Abstract][Full Text] [Related]
4. [The combination of indacaterol and glycopyrronium has effects on symptoms, lung function, and rate of exacerbations in COPD patients].
Ulrik CS
Ugeskr Laeger; 2014 Sep; 176(38):. PubMed ID: 25294211
[TBL] [Abstract][Full Text] [Related]
5. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.
Ulrik CS
Int J Chron Obstruct Pulmon Dis; 2014; 9():331-8. PubMed ID: 24729699
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
[TBL] [Abstract][Full Text] [Related]
7. Indacaterol/glycopyrronium bromide fixed-dose combination for the treatment of COPD.
Schachter EN
Drugs Today (Barc); 2013 Jul; 49(7):437-46. PubMed ID: 23914352
[TBL] [Abstract][Full Text] [Related]
8. [LAMA/LABA fixed dose combination for treatment of COPD].
Kuwahira I
Nihon Rinsho; 2016 May; 74(5):820-6. PubMed ID: 27254953
[TBL] [Abstract][Full Text] [Related]
9. Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study.
Salomon J; Stolz D; Domenighetti G; Frey JG; Turk AJ; Azzola A; Sigrist T; Fitting JW; Schmidt U; Geiser T; Wild C; Kostikas K; Clemens A; Brutsche M
Respir Res; 2017 Jan; 18(1):13. PubMed ID: 28077140
[TBL] [Abstract][Full Text] [Related]
10. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
Horita N; Kaneko T
Int J Chron Obstruct Pulmon Dis; 2015; 10():813-22. PubMed ID: 25960646
[TBL] [Abstract][Full Text] [Related]
11. Seebri Neohaler and Utibron Neohaler for COPD.
Med Lett Drugs Ther; 2016 Mar; 58(1491):39-41. PubMed ID: 27027687
[No Abstract] [Full Text] [Related]
12. Improvement in health status with once-daily indacaterol/glycopyrronium 110/50 μg in COPD patients: real-world evidence from an observational study in Ireland.
O'Doherty B; Dorman J; McGrath K; Kelly K; Molony D; Lacey S; Whelan S; Schmid S; Sullivan S
Ir J Med Sci; 2019 Nov; 188(4):1251-1259. PubMed ID: 30924006
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic review.
Rodrigo GJ; Plaza V
Chest; 2014 Aug; 146(2):309-317. PubMed ID: 24556877
[TBL] [Abstract][Full Text] [Related]
14. Relationship between lung function and inhalation devices for LAMA/LABA therapy for chronic obstructive pulmonary disease.
Yamada H; Hida N; Satoh H; Nakaizumi T; Terashima H; Hizawa N
Chron Respir Dis; 2018 Nov; 15(4):419-420. PubMed ID: 29152998
[No Abstract] [Full Text] [Related]
15. Computed tomography (CT)-assessed bronchodilation induced by inhaled indacaterol and glycopyrronium/indacaterol in COPD.
Shimizu K; Seto R; Makita H; Suzuki M; Konno S; Ito YM; Kanda R; Ogawa E; Nakano Y; Nishimura M
Respir Med; 2016 Oct; 119():70-77. PubMed ID: 27692151
[TBL] [Abstract][Full Text] [Related]
16. Combination of glycopyrronium and indacaterol inhibits carbachol-induced ERK5 signal in fibrotic processes.
Namba Y; Togo S; Tulafu M; Kadoya K; Nagahama KY; Taka H; Kaga N; Orimo A; Liu X; Takahashi K
Respir Res; 2017 Mar; 18(1):46. PubMed ID: 28284212
[TBL] [Abstract][Full Text] [Related]
17. Combined long-acting bronchodilator single therapy for COPD.
Râjnoveanu RM; Antoniu S; Ulmeanu R
Expert Opin Pharmacother; 2014 Jan; 15(1):139-42. PubMed ID: 24283778
[TBL] [Abstract][Full Text] [Related]
18. Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone in Patients with COPD-A Cost-Effectiveness Analysis in the Czech Republic.
Skoupa J; Kasak V; Klimes J; Valena T
Value Health Reg Issues; 2018 Sep; 16():112-118. PubMed ID: 30539739
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Double Bronchodilation (LABA+LAMA) in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Lung Cancer.
Leiro-Fernández V; Priegue Carrera A; Fernández-Villar A
Arch Bronconeumol; 2016 Dec; 52(12):622-623. PubMed ID: 27372542
[No Abstract] [Full Text] [Related]
20. Indacaterol/Glycopyrronium in Clinical Practice: The Italian Experience.
Cazzola M
Respiration; 2018; 95 Suppl 1():1-2. PubMed ID: 29705778
[No Abstract] [Full Text] [Related]
[Next] [New Search]
